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Cardiovascular disease, a leading cause of mortality in developed countries, is mainly caused by atherosclerosis, a chronic
inﬂammatory disease. Macrophages, which diﬀerentiate from monocytes that are recruited from the blood, account for the
majorityofleukocytes inatheroscleroticplaques. Apoptosisandthesuppressedclearance ofapoptoticmacrophages (eﬀerocytosis)
are associated with vulnerable plaques that are prone to rupture, leading to thrombosis. Based on the central functions
of macrophages in atherogenesis, cytokines, chemokines, enzymes, or microRNAs related to or produced by macrophages
have become important clinical prognostic or diagnostic biomarkers. This paper discusses the impact of monocyte-derived
macrophages in early atherogenesis and advanced disease. The role and possible future development of macrophage inﬂammatory
biomarkers are also described.
1.Introduction
Cardiovascular disease (CVD) is the leading cause of mortal-
ity in developed countries and is likely to attain this status
worldwide, accounting for 16.7 million deaths each year
[1, 2]. Coronary artery disease (CAD) and cerebrovascular
disease are the most common forms of CVD, whose underly-
ing pathological feature is atherosclerosis. Atherosclerosis is
a slowly progressing chronic disease of large and medium-
sized arteries which is characterised by the formation of
atherosclerotic plaques consisting of necrotic cores, calciﬁed
regions, accumulated modiﬁed lipids, migrated smooth
muscle cells (SMCs), foam cells, endothelial cells (ECs), and
leukocytes [3].
Since the term arteriosclerosis was ﬁrst introduced by
Jean Lobstein in 1829 [4], it has long been believed that
atherosclerosis involved the merely passive accumulation of
cholesterol in arterial walls. In the 1970s, the response-
to-injury model was described [5]. Today, the picture
of atherosclerosis is much more complex as it has been
considered a chronic inﬂammatory disease, involving both
the innate and adaptive immune systems, which modulate
the initiation and progression of the lesions, and potentially
devastating thrombotic complications [6]. Understanding
the principles of the inﬂammatory processes is important for
deciphering the complex processes involved in atheroscle-
rosis progression. Atherosclerotic plaques are characterised
by an accumulation of lipids in arterial walls together
with inﬁltration of immunocytes. The degree of inﬂux of
inﬂammatory cells to atherosclerotic lesions is determined
based on monocyte recruitment, macrophage egress, and the
balance of proliferation, survival, and apoptosis within the
arterial walls [7].
Macrophages are the ﬁrst inﬂammatory cells to invade
atherosclerotic lesions, and they are the main component
of atherosclerotic plaques [8]. Inﬂammatory cytokines pro-
duced by macrophages stimulate the generation of endothe-
lial adhesion molecules, proteases, and other mediators,
which may enter systemic circulation in soluble forms
[9]. Cytokines as inﬂammatory biomarkers, independent of
cholesterol and regulators of blood pressure, could yield
more information on diﬀerent aspects of pathogenesis of
atherosclerosis [10]. This paper discusses the central roles of
macrophages in every stage of atherosclerosis, focusing on2 Mediators of Inﬂammation
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Figure 1: The roles of M1 and M2 macrophages. Ly6C high monocytes diﬀerentiate into M1 type, classically activated macrophages that
aﬀect proteolysis and produce antibacterial products. Ly6C low monocytes diﬀerentiate into M2 type, alternatively activated macrophages
that are involved in wound repair and tissue remodelling. M1 and M2 cells secrete diﬀerent cytokines that function in eﬀerocytosis and the
f o r m a t i o no ff o a mc e l l s .
the role of inﬂammatory biomarkers in predicting primary
cardiovascular events related to macrophages.
2. Initiationand Early Progressionof
Atherosclerosis
2.1. Recruitment and Entry of Monocytes to Arterial Walls.
Monocytes originate from bone marrow-derived progenitor
cells and do not proliferate in the blood [11]; their functions
under homeostatic conditions remain unclear. The mecha-
nisms of monocyte homing to healthy aortas are not well
deﬁned; more is known about monocyte recruitment into
aortas during atherogenesis [12]. During the pathogenesis
of atherosclerosis, blood monocytes inﬁltrate from blood
to the intima and subintima [13] ,ap r o c e s sw h i c hi s
activated by subendothelial accumulation of apolipoprotein
B-containing lipoproteins (apoB-LPs) [14]. Summoned by
chemokinesis, monocytes roll over and become tethered to
endothelial cells overlying retained apoB-LPs through inter-
actions between monocyte P-selectin glycoprotein ligand-1
(PSGL-1) and endothelial selectins [14]. E-selectin overlaps
with P-selectin to support rolling [15]. After monocytes roll
on the inﬂamed aortic endothelium, they use lymphocyte
function-associated antigen-1 (LFA-1), very late antigen-
4 (VLA-4) and their respective endothelial cell ligands,
including vascular cell adhesion molecule (VCAM-1) and
intercellular adhesion molecule-1 (ICAM-1), to slow rolling
and form tighter adhesions [16]. Finally, ﬁrm adhesion is
followedbyentryofmonocytesintothesubendothelialspace
(diapedesis) [17]( Figure 1).
In mice, monocytes can be identiﬁed from other cir-
culating cells by the diﬀerential expression of chemokine
C-C motif receptors 2 (CCR2), chemokine C-X3-C motif
receptor 1 (CX3CR1), and Ly6C antigen, which is mono-
cyte/macrophage cell diﬀerentiation antigen regulated by
interferon gamma [11]. Apolipoprotein E–/– (Apoe–/–)
mice, a model system for atherosclerosis, are prone to
develop atherosclerosis because they have high levels of
the atherogenic lipoprotein known as remnant lipopro-
tein [18]. Ly6ChighCCR2+CX3CR1Low monocytes, which
are precursors of inﬂammatory macrophages, have been
observed to adhere to activated endothelium in Apoe–/–
mice [19]. In contrast, little is known about how a lack
of apoE aﬀects inﬂammatory Ly6ClowCCR2−CX3CR1high
monocytes [20]. These studies suggest that there is persistent
recruitment of inﬂammatory monocytes into established
atherosclerotic lesions (Figure 2). These studies described
above are limited in mice and it may be diﬃcult to interpret
humanmacrophagesubsets,buttwomajorsubsetsofhuman
macrophagescanbedeﬁned:CD14highCD16low macrophages
typically represent 85% ∼ 95% monocytes in healthy
individuals; CD14lowCD16high macrophages are comprised
in the remains [21] .T h er o l eo fe a c hs u b s e ti nh u m a n
atherosclerosis remains unknown.
2.2. Monocyte Diﬀerentiation into M1 and M2 Subsets
of Macrophages. Driven by macrophage colony-stimulatingMediators of Inﬂammation 3
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Figure 2: Signalling pathways in a macrophage involved in atherosclerosis. Pro- and anti-inﬂammatory factors act on macrophages, leading
to activation of downstream scavenger receptors (SRs)/toll-like receptors (TLRs)-NF-κB signalling, endoplasmic reticulum (ER) stress and
eﬄux of cholesterol via ABCA and ABCG transporters.
factor (M-CSF) and other diﬀerentiation factors, monocytes
diﬀerentiate into two major types of macrophages and/or
dendritic cells [22, 23]. M1 and M2 macrophages play
opposite roles during inﬂammation, although both are
present in atherosclerotic lesions. M1 macrophages, which
are diﬀerentiated from Ly6Chigh monocytes and promote
inﬂammation, are classically activated by lipopolysaccharide
in the presence of IFN-γ, leading to the production of high
levels of IL-2, IL-23, IL-6, IL-1, and TNF-α. In contrast,
activated M2 macrophages, which are diﬀerentiated from
Ly6Clow monocytes and promote resolution inﬂammation,
diﬀerentiate in the presence of IL-4, IL-13, IL-1, or vitamin
D3 and tend to produce a large amount of IL-10 and express
scavenger receptors, mannose receptors, and arginase [24]
(Figure 2). Recently, there has been a great deal of interest
in macrophage heterogeneity in atherosclerotic lesions, par-
ticularly regarding the roles of M1 versus M2 macrophages.
There is evidence that an imbalance in the ratio of classically
activated M1 and alternatively activated M2 macrophages
in advanced atherosclerosis impair resolution in vitro [25],
but a clear picture has not yet emerged from these studies
[23]. Most of the hypotheses in this area have been driven
by in vitro studies exploring gene expression patterns and
functionalattributesofmonocytesormacrophagessubjected
to various treatments, including growth factors, cytokines
derived from helper T cells [26], the transcription factors
peroxisome proliferators-activated receptors (PPARs) γ [27],
and the bioactive lipid sphingosine-1-phosphate [28]. How-
ever, there is a signiﬁcant diﬀerence between in vitro and
in vivo results, which makes atherogenesis more complex.
Future projects should focus on the characterisation of
macrophageheterogeneitywithrespecttodiﬀerentialexpres-
sion of speciﬁc molecular biomarkers that have functional
signiﬁcance for atherogenesis [29]. Additional attention
should be paid to the roles of cytokines in controlling
monocytes that diﬀerentiate into dendritic cells (DCs) rather
than macrophages.
2.3. Important Receptors and Transporters for Cholesterol
Loading and Eﬄux in the Toll-Like Receptors of Macrophages.
In the innate immune system, toll-like receptors (TLRs)
are the primary receptors that recognise highly conserved
structural motifs of pathogens [30]. Under hyperlipidemic
conditions, TLRs likely participate in the regulation of
atherosclerosis. The activation of TLRs induces the pro-
duction of proinﬂammatory cytokines and nitric oxide in
macrophages and the induction of DC maturation, leading
to the upregulation of costimulatory molecules, such as
CD80 and CD86. In addition, TLR1, TLR2, TLR4, and TLR6
are expressed in atherosclerotic lesions. A large number
of pathogen-associated molecules can activate TLRs. Heat-
shock proteins (hsp60) [31] and oxidised (ox) LDL [32]
mediate at least a part of their eﬀects within atherosclerotic
plaques through TLR4 binding. TLR2, expressed on cells
that do not derive from bone marrow, appears to promote
atherogenesis in mice [33]. Interestingly, Sun et al. showed
that free cholesterol (FC) accumulation in the endosomal
compartment increases the inﬂammatory response in a TLR-
dependent fashion, and TLR3 is the predominant receptor
involved in this process [34]( Figure 3).
2.4. Scavenger Receptors. Macrophage scavenger receptors
(SRs) are found to bind and internalise modiﬁed forms
of LDL through mechanisms that are not inhibited by
cellular cholesterol content, and they are likely responsible4 Mediators of Inﬂammation
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Figure 3: The fate of macrophages in an early lesion of atherosclerosis. The accumulation of apolipoprotein B-lipoproteins (apoB-LPs) in
the matrix beneath the endothelial cell layer leads to the recruitment of monocytes. The cells diﬀerentiating into macrophages undergo foam
cell formation, leading to apoptosis. Because eﬀerocytosis works eﬃciently, this lesion does not develop necrotic core. The resolution of the
inﬂammation results in decreased plaque progression.
for macrophage cholesterol accumulation [35]. SR class A
(SR-AI and AII), expressed on the surface of macrophages,
account for the uptake of acetylated LDL in the majority of
macrophages, but macrophages preferentially bind oxLDL,
recognising the modiﬁed apoB components of the particles
[36]. Interestingly, SR-As expression is increased in animals
with low atherosclerotic responses, suggesting that this path-
way is protective. Furthermore, overexpressing a secreted
form of the extracellular domain of human SR-A resulted
in a 20% reduction in monocyte/macrophage adherence to
endothelial cells in atherosclerotic lesions in Ldlr–/– mice
[37]. Thus, the use of such decoy SRs may prove beneﬁcial
for retarding the development of early atherosclerotic lesions
(Figure 3).
Other studies indicate that SR class B CD36 plays a major
role in the clearance of oxLDL, contributing 60% to 70%
of cholesterol ester accumulation in macrophages exposed
to LDL oxidised by Cu+2 and myeloperoxidase/peroxynitrite
[38, 39]. CD36 activates signalling via TLR2 and TLR6 in
response to lipoteichoic acid and diacylated macrophage-
activity lipopeptide 2 [40, 41]. In addition, a newly described
TLR heterodimer of TLR4/6 has been shown to cooperate
with CD36 in activating NF-κB in response to oxLDL [42]
(Figure 3).
SR-BI and SR-BII share 30% sequence homology with
CD36 and both can bind modiﬁed forms of LDL as well as
nativeHDL,LDL,andVLDL[43](Figure 3).Thesereceptors
have a major impact on lipoprotein metabolism through two
mechanisms:(1)SR-BImediatescholesteroltransfertoHDL,
and (2) SR-BI facilitates selective delivery of lipoproteins
from HDL to steroidogenic tissues for excretion into bile
and feces in the liver [35]. Although the antiatherogenic
eﬀects of SR-BI have been largely attributed to mediation of
cholesterol ester uptake in the liver, this receptor is highly
expressed on foam cells in human and mouse atherosclerotic
lesions, where it may inﬂuence lesion development by
aﬀecting both the uptake of lipoproteins and the eﬄux of
cholesteroltoHDL[44].TheotherclassDSRs,CD68,andits
murine homolog macrosialin are predominantly expressed
in late endosomes and lysosomes of macrophages and may
play a role in endolysosomal processing for oxLDL [45]
(Figure 3).
2.5. ATP-Binding Cassette Transporters, Subset A and G
(ABCA and ABCG). Free cholesterol released from lyso-
somes and rehydrolysed cholesteryl ester droplets can also
traﬃc to the plasma membrane and thus be available for
eﬄux out of the cells [46]. Cholesterol eﬄux is thought to be
a major process involved in plaque regression when hyperc-
holesterolemia is reversed. The mechanisms and exact route
of cholesterol transport to the plasma membrane are not
fully known, although Golgi-to-plasma membrane vesicular
transport may be involved [47]. Once at the plasma mem-
brane, cholesterol is transferred to the outer leaﬂet, where
it is removed from cells by ABCA1- and ABCG1-mediated
transport to apolipoprotein A1 and HDL, respectively, or by
“passive diﬀusion” to cholesterol-poor HDL [48]. As pre-
dicted, genetic deﬁciencies of ABCA or ABCG could account
forenhancedinﬂammationinatherosclerosis,especiallyafter
treatment with TLR ligands [49] and result in foam cell
formation and further acceleration of atherosclerosis [50].Mediators of Inﬂammation 5
Extensive work in vitro and in vivo has focused on how
sterol-regulated transcription factors, liver X receptors LXRa
and LXRb (LXR), induce ABCA1 and ABCG1 and promote
regression of foam cell lesions through this and other
mechanisms [51]. Free cholesterol (FC) within macrophages
has recently been proposed as an initiator of a proinﬂam-
matory signalling response in developing atherosclerotic
lesions [52]. Oxysterols, from FC phagocytosis, are LXR
agonists and increase reverse cholesterol transport (RCT)
from macrophages by increasing expression of macrophage
apolipoprotein E (apo E) and the cholesterol eﬄux trans-
porters ABCA1 and ABCG1. This is likely an important
part of the mechanism for LXR-dependent protection from
atherosclerosis because these eﬀects are not observed in LXR
knockout mice [53]. Because accumulation of FC within
macrophages at sites of atherosclerotic lesions converts them
into foam cells [54]b ys t i m u l a t i n gR C T ,L X Rr e d u c e s
foam cell formation and lesion cholesterol content directly
(Figure 3).Asatherapeuticstrategytopromotelesionregres-
sion, investigators have attempted to enhance macrophage
cholesterol eﬄuxbyincreasingHDLorHDL-likeparticlesor
by increasing ABC transporters [48]. Though no drugs have
yet been approved for this purpose, this approach continues
to be a major focus of cardiovascular drug discovery.
2.6. Apoptosis of Macrophages in Early Atherosclerotic Lesion.
The mechanism and role of macrophage apoptosis in early
lesions are still not well understood. It is diﬃcult to detect
macrophage apoptosis in early lesions because apoptotic
cells are rapidly cleared by the adjacent macrophages
through phagocytosis (known as eﬀerocytosis), which will
be described later in the section of advanced progression
in atherosclerosis (Figure 1). Several studies determined the
eﬀect of apoptosis on the progression of atherosclerosis.
Ldlr–/– mice develop high levels of LDL when placed on a
high-fat diet, because their hepatocytes lack LDL receptors
and thus cannot eﬃciently eliminate the atherogenic LDL
particles from the blood [55]. In Ldlr–/– mice in which bone
marrow derived cells, including regional macrophages, are
deﬁcient of the proapoptotic protein Bax, the aortic lesions
showed decreased macrophages apoptosis. Additionally,
these lesions were larger and more macrophage-rich [56].
Conversely,Ldlr−/−mice,whichlacktheprosurvivalprotein
AIM, showed an increase in apoptosis of early regional
macrophages and developed smaller atherosclerotic lesions
[57]. Thus, the apoptosis of the early regional macrophages
is associated with lesion size and plaque progression. Deﬁ-
ciency of phospholipase Cβ3r e s u l t e di ne n h a n c e ds e n s i t i v i t y
ofnewlyrecruitedmacrophagestooxLDL-inducedapoptosis
in early lesions, accompanied by a concomitant decrease in
atherosclerosis [58]. Because knocking out phospholipase
Cβ3 does not appear to change the mouse phenotype,
this may be an attractive target to modulate macrophage
apoptosis.
3. Advanced ProgressioninAtherosclerosis
Macrophages in advanced atherosclerosis contribute to the
plaque morphology, thinning the ﬁbrous cap, and necrotic
core, which can lead to increased pro-inﬂammatory re-
sponses and further apoptotic signals for SMCs, ECs, and
leukocytes within the plaques [59] .T h ev u l n e r a b l ep l a q u ei s
prone to rupture and induction of thrombosis. In autopsy
specimens containing atherosclerotic lesions, rupture sites
were responsible for the acute vascular events [60]. The
rupture sites, which are located on the shoulder of raised
lesions, are almost always in the areas close to plaques’
necroticcores,andareassociatedwiththethinningofﬁbrous
caps. One of the most important questions in atherosclerosis
is how macrophages contribute to this advancement in
plaque progression (Figure 4).
Macrophages decrease intimal myoﬁbroblast-like SMCs
and degradation of collagens [61]( Figure 4). In vitro data
show that macrophages can trigger apoptosis of SMCs by
activating the Fas apoptotic pathway and secreting proapop-
totic TNFα and nitric oxide [62]. Macrophages may also
decrease collagen synthesis in intimal SMCs through the
secretion of macrophage-derived matrix metalloproteinases
(MMPs) to decrease collagen synthesis [63]. MMPs may also
be involved in thinning of the ﬁbrous cap. In a study that
attempted to look directly at plaque disruption, macrophage
overexpression of MMP-9 had little eﬀect on Apoe−/− mice
due to a lack of MMP activation in plaques, but the over-
expression of a constitutively active mutant form of MMP-9
resulted in plaque ﬁssures [64]. Further details about TNFα
and MMPs are discussed below in the biomarkers section.
3.1. Plaque Necrosis and Macrophage Death in Advanced
Atherosclerotic Lesions. Plaque necrosis contributes to in-
ﬂammation, thrombosis, plaque breakdown, and physical
stress on the ﬁbrous cap [65]. Necrotic cores arise from the
combination of apoptosis of macrophages and the phago-
cytic clearance of the apoptotic cells in advanced plaques
[18]. There is emerging evidence that SR-A plays diﬀerent
roles in early and advanced atherosclerotic lesions. As we
described previously, SR-A has the protective function in
early lesions. However, in advanced atherosclerotic lesions,
i nwh i c hm a c r o p h a g ec e lld e a t hl e a d st on e c r o t i cc o r ef o rm a -
tion and plaque destabilisation, SR-A may have important
roles in both the induction of apoptosis and clearance
of these dying cells. In hypercholesterolemia, macrophage
pathwaysformetabolising modiﬁed lipoproteins arethought
to be overwhelmed, leading to a toxic accumulation of free
cholesterolinthecellsthatresultintheendoplasmicreticular
stress. In this setting, the engagement of SR-A pathways
by modiﬁed lipoproteins or fucoidan triggers apoptotic
cell death, indicating that the SR-A signalling contributes
to macrophage death and necrotic core formation [66].
However, this proatherosclerotic role is also balanced by the
ability of SR-A to recognise and clear apoptotic cells in a
nonphlogistic manner. These additional functions of SR-A
must be considered when proposing therapies to inhibit this
pathway. Longer-term studies of SR-A manipulation will be
required to determine the impact of this receptor at later
stages of atherosclerosis.
A number of processes in advanced lesions may trigger
macrophage death, and it is almost certain that a combi-6 Mediators of Inﬂammation
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Figure 4: Cellular interactions with macrophages in an advanced lesion. Foam cells accumulate in the intima and undergo apoptosis that
is triggered by cytokines. Eﬀerocytes do not function properly, and apoptotic cells secondarily become necrotic cells, contributing to the
formation of a necrotic core. Necrosis of macrophages and SMCs decrease collagen synthesis to diminish the collagen content of the ﬁbrous
cap, triggering rupture and thrombosis.
nation of factors and processes plays a role in vivo.A
potential role for these processes is supported primarily
by studies with cultured macrophages. The endoplasmic
reticulum (ER) stress, primarily established by Tabas labo-
ratory, may lead signiﬁcantly to macrophage apoptosis and
generation of necrotic core [67]. The high levels of ER
stresses, such as intracellular oxysterols, lead to activate the
unfolded protein response (UPR) pathway, which increases
the expression of a proapoptotic protein, called CEBP-
homologous protein (CHOP) [68]. The elevation of CHOP
can trigger macrophage apoptosis by several mechanisms,
but recent work shows a speciﬁc apoptotic mechanism
involving calcium channel activity in the ER lumen [69].
Most importantly, a deﬁciency of CHOP in the models of
advanced atherosclerosis suppresses advanced lesions due to
macrophageapoptosisandplaquenecrosis.Calciumreleased
from the ER can trigger apoptosis through excess uptake into
mitochondria that activates calcium/calmodulin-dependent
protein kinase II (CaMKII), which, in turn, promotes
cell apoptosis by activating both Fas death receptor and
mitochondrial membrane permeabilization [69]. Another
system may provide subtle ER stress, in which a “sec-
ond hit” is needed to trigger apoptosis [70]( Figure 3).
In this system, ER stress and macrophage apoptosis are
induced by low-dose ER stressors including thapsigargin
or 7-ketocholesterol, and combination of pattern recog-
nition receptors activation as the “second hits”, each of
which is unable to induce apoptosis by themselves [70]
(Figure 3). An example of PRR activation is activators of
SR-A and TLR 4, such as oxLDL. The other experiment
demonstrated that activators of CD36 and TLR2/6, such as
oxLDL and oxidized PLs (oxPL), can enhance the apoptosis
pathways [67]( Figure 3). The role of SR-A and CD36
as the “second hits” for ER stress-induced apoptosis was
demonstrated by a mouse model in which these receptors
were targeted, with a result that apoptosis of advanced
regional macrophages and plaque necrosis were deceased
[71]. In humans, advanced plaques show similar results
to those seen in mice. Autopsy specimens from human
coronary arteries with heart disease showed a correlation
with expression of markers of the UPR, including CHOP,
apoptosis, and advanced plaque stage [72].
Notably, macrophage apoptosis does not trigger plaque
necrosis. Plaque necrosis and rupture occurs when apop-
totic cells are not cleared suﬃciently. Tabas called this
phenomenon eﬀerocytosis, which describes the phagocytic
clearance of apoptotic cells [18]. Eﬀerocytosis in early lesions
prevents cellular necrosis and triggers anti-inﬂammatory
pathwaysthroughTGF-β andtheactivationoftheNF-κBcell
survival pathway (Figure 1)[ 73]. However, how eﬀerocytosis
becomes defective in advanced lesions is still unknown. It is
assumed that the eﬀerocytosis does not occur in advanced
lesions, resulting in defective anti-inﬂammatory signalling
(Figure 4)[ 18].
4.BiomarkersasRiskFactorsAssociated
with Macrophages in Atherosclerosis
Given the new understanding of inﬂammation in atheroscle-
rosis and their central role of macrophages, inﬂamma-
tory biomarkers for disease progression in atherosclerosis
should be independent of cholesterol and regulators of
blood. In this regard, we will discuss biomarkers related toMediators of Inﬂammation 7
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related to macrophages. All of these inﬂammatory markers and
mediators, released at diﬀerent stages of progression in atheroscle-
rosis, can enter the circulation, aﬀecting the prognosis of patients
with atherosclerosis.
macrophagesandinﬂammationinatherosclerosis(Figure 5).
As our understanding of the biology of atherothrombosis
has improved [74], several studies have evaluated a series
of candidate biomarkers of inﬂammation, oxidative stress,
and thrombosis as potential clinical tools to improve the
prediction of risk in atherosclerosis [75, 76]. Although there
are hundreds of papers that discuss the important functions
ofmanymediatorsofatherosclerosis,thedistinctionbetween
biomarkers versus mediators of disease has proven quite
confusing. As discussed above, a particular molecule may
participate clearly in a pathogenic pathway but not serve
as an eﬀective biomarker. For example, soluble VCAM-1 is
not a useful indicator of risk of future myocardial infarction
in apparently healthy men [77]. However, researchers have
demonstrated that VCAM-1 is essential for the initiation of
an atherosclerotic lesion [78].
4.1. Involvement of Cytokines Secreted by
Macrophages in Atherosclerosis
4.1.1. Tumour Necrosis Factor-α (TNF-α). TNF-α regulates
a number of critical cell functions including cell prolifera-
tion, survival, diﬀerentiation, and apoptosis. Macrophages
produce TNF-α induced by TLRs and are also highly
responsive to TNF-α through the TNF receptor (TNFR)
[79, 80]. One of the various functions is a pivotal role
in orchestrating the production of a pro-inﬂammatory
cytokine cascade. TNF-α is thus considered to be a “master
regulator” of pro-inﬂammatory cytokine production [81].
TNF-α-deﬁcient Apoe−/− m i c es h o war e d u c t i o ni nl e s i o n
formation, with a concomitant decrease in VCAM-1 and
ICAM-1 expression, which are important for monocyte
rolling on endothelial cells as mentioned previously [82].
In contrast, mice deﬁcient in the TNF-α receptor (TNFR)
develop larger lesions than control mice [83]. In addition
to these roles, Witsell and Schook [84] demonstrated that
TNF-α has macrophage diﬀerentiation capabilities. TNF-α
genetranscriptsareexpressedduringdiﬀerentiationofbone-
marrow-derived macrophages. TNF-α aﬀects the develop-
ment of atherosclerosis at the fatty streak stage, and cleavage
of TNF is an important step in activating the proatherogenic
properties of TNF-α [85].
4.1.2. Interleukin 1 (IL-1). IL-1 stimulation initiates leuko-
cyte adhesion to ECs for macrophage transmigration and
contributes to slowly progressing inﬂammatory processes
that take place in atherosclerosis [86]. Studies involving
blocking IL-1ra antibodies in Apoe−/− mice and with
Ldlr−/− transgenic mice that overexpress IL-1 or that have
a deﬁciency in IL-1β clearly show that IL-1 is involved in
atherogenesis [87]. Yet, although the circulating levels of IL-
1, evenin severeinﬂammatory diseases,are undetectable,the
availabilityofanti-IL-1antibodieswilllikelybeveryusefulin
the future [86].
4.1.3. IL-12. IL-12 is a key Th1 cytokine that is produced
mainly by plaque macrophages and stimulates the prolifer-
ation and diﬀerentiation of NK cells and T cells. IL-12 is
detected in the aortas of Apoe–/– mice, and the adminis-
tration of IL-12 results in enhanced lesion size in Apoe−/−
recipients [88]. IL-12 p40-deﬁcient Il12b−/−Apoe−/− mice
have a 52% reduction of the plaque area at 30 weeks, but
not at 45 weeks of age [89]. T lymphocyte recruitment
into the intima was accelerated in early and advanced
atherosclerotic lesions [16]. Most of the T cells are TCRαβ
CD4+ cells with an activated phenotype, and a few express
CD8+ or TCRγδ [90]. Interestingly, analysing CD4+ T cells
showedthatIL-12upregulatesCCR5expression,chemotaxis,
and transendothelial migration toward CCL5 through IL-12
receptors [91].
4.1.4. IL-18. IL-18 is produced by macrophages and admin-
istration of IL-18 antibodies accelerates development of
atherosclerotic lesions in Apoe−/− mice. IL-18 seems to
enhance atherosclerosis by increasing IFN-γ [92]. Although
IL-18 is not currently considered a useful tool for the
presence of subclinical atherosclerosis in general population
[93], the AtheroGene Study indicates that high serum
concentrations of IL-18 likely cause cardiovascular death in
patients with coronary artery disease [94].
4.1.5. Soluble CD40 Ligand (CD40L). Macrophages, T lym-
phocytes, ECs, SMCs, and DCs express CD40L, whereas
CD40 is found on macrophages, ECs, and SMCs from
atherosclerosis-prone vessels [9]. The interaction of CD40
with CD40L plays a signiﬁcant role in thrombosis, but it
also contributes to modulation of the immune response
in plaques. Treatment with antibodies against CD40L
reduces atherosclerosis in Ldlr−/− mice, with a concomitant8 Mediators of Inﬂammation
decrease in macrophages and T cells and a reduction
in VCAM-1 expression [95]. Further experiments using
Cd40lg−/−Apoe−/− mice have demonstrated a proathero-
genic role for CD40L in advanced atherosclerosis by pro-
moting lipid core formation and plaque destabilisation [96].
Because preanalytical sampling conditions critically inﬂu-
ence the soluble CD40L concentration, only plasma samples
are appropriate for CD40L measurement [97]. Although
CD40L is critical for the development of advanced lesions
in animal experiments, the Dallas Heart Study suggests that
CD40L is not identiﬁed in subclinical atherosclerosis in the
general population [98]. However, high concentrations of
CD40L are associated with increased vascular risk in healthy
women according the results of the Women’s Health Study
[99].
4.2. Anti-Inﬂammation Factors
4.2.1. IL-10. IL-10, which is derived from monocytes and
macrophages, is an important anti-inﬂammatory regula-
tor for the development of advanced atherosclerosis. As
expected, IL-10-deﬁcient mice showed a decreased amount
of collagen, induced by IFN-γ production in the atheroscle-
rotic vessels [100]. Studies with Il10−/−Apoe−/− mice
conﬁrmed the atheroprotective properties of IL-10 in early
stage atherosclerosis and showed that IL-10 promotes the
stability of advanced plaques [101]. IL-10 is not a prognostic
marker for cardiovascular diseases. Although, it is possible
to test serum concentrations of IL-10, we anticipate future
studies on the involvement of this marker.
4.2.2. TGF-β. Several cell types, including macrophages,
produce TGF-β. Studies with animal models suggest that
local(ratherthansystemic)alterationsinTGF-β activitymay
be important during atherogenesis and that TGF-β levels
in tissues may be more informative than those in blood
[102]. Apoe−/− mice that express a dominant-negative
form of TGF-β receptor II in T cells clearly demonstrated
substantialrolesforTGF-βincontrollingtheTh1responsein
atherosclerosis [103]. Several studies suggest that TGF-β lev-
elsarereducedatsitesofatheroscleroticplaquedevelopment.
Introducing blocking antibodies against TGF-β or treatment
with soluble TGF-β receptor II accelerates atherosclerosis
with a signiﬁcant loss of collagen content [87]. Although
a direct measure of the ligand is technically demanding,
associations between heart disease and genetic polymor-
phisms that are known to modulate ligand production
might prove more accessible. Furthermore, such associations
would support a causal relationship between altered TGF-
β production and diseases [102]. A number of studies have
examined the association between these polymorphisms and
cardiovasculardiseasestatus.Alargestudyofmorethan6000
individuals who were involved in the Rotterdam study found
an association between TGF-β1 polymorphisms and stroke
(another pathology associated with plaque rupture, but in
ad i ﬀerent vascular ﬁeld) [104]. Recently, using autopsy
sections of atherosclerosis in a Japanese population, Oda et
al. observed a signiﬁcant association between atherosclerosis
and the only TGF-β1 gene polymorphism, at least in some
artery ﬁelds [105]. Taken together, these studies suggest
that decreasing production of TGF-β1 ligands might favour
unstable lesion phenotypes without aﬀecting the plaque
burden, once again highlighting the need to carefully select
the cardiovascular endpoint under study.
4.3. Chemokines Produced by Macrophages in Atherosclerosis
4.3.1. Chemokine Receptor CCR5. CCR5 was initially known
as a coreceptor on macrophages for HIV infection. However,
evidence now supports a role for CCR5 and its ligands CCL3
(MIP-1a), CCL4 (MIP-1b), and CCL5 (RANTES) in the
initiation and progression of atherosclerosis [106]. Although
there is no CCR5 in normal coronary arteries, CCR5
immunoreactivity is detected in atherosclerotic lesions,
suggesting colocalisation of VSMC with macrophages [107].
It has been suggested that CCR5 may be more impor-
tant in the later stages of plaque development [108]. A
recent study found more than 50% reduction in the size
of plaque lesions in the aortic root and the abdominal
aorta of Apoe−/−Ccr5−/− mice and fewer macrophages
in lesions compared with Apoe−/− mice [109]. The com-
bined inhibition of three chemokine–receptor systems,
MCP-1 (CCL2)/CCR2, fractalkine (CX3CL1)/CX3CR1, and
CCL5/CCR5, was reported to abolish development of
atherosclerosis in an Apoe−/− mouse model [110], sup-
porting nonredundancy of these chemokines with regard to
monocyte mobilisation in atherosclerosis. Compared with
chemokine receptors, the ligands CCL3, 4, and 5 seem to be
better choices for biomarkers in atherosclerosis because it is
possible to test their mRNA levels in circulating leukocytes.
TheroleofCCL3andCCL4actingonCCR5inatherogenesis
is less well deﬁned, but these chemokines also appear to be
important in atheroma progression and inﬂammatory cell
recruitment into plaques [111]. In particular, ﬁndings from
animal models indicate that CCL5 plays a greater role in
the development of atherosclerotic plaque than other CCR5
ligands [112].
4.4. Macrophage Migration Inhibitory Factor (MIF). MIF is
produced by macrophages in early and advanced atheroscle-
rotic lesions. The role of MIF with respect to inﬂammatory
cell recruitment in atherosclerotic plaque progression has
been described [113]. A study of Mif−/−Ldlr−/− mice
suggested that MIF is involved in atherosclerosis through
the regulation of lipid deposition, protease expression,
and intimal thickening [114]. Because MIF can be readily
measured in plasma and other tissue ﬂuids in diﬀerent
disease states [115], the diﬀerent roles of MIF as a biomarker
in pathogenesis and progression of atherosclerosis are an
important area of inquiry.
4.5. Inﬂammation-Regulating Enzymes: Matrix Metallopro-
teinases (MMPs). Macrophage-derived MMPs are involved
inthethinningoftheﬁbrouscap[116].MMPsareafamilyof
protease-activated enzymes that degrade extracellular matrix
(ECM) proteins. The regulation of MMPs is complex; onceMediators of Inﬂammation 9
activated, an MMP can activate others. Studies showing
a temporal and spatial correlation between the presence
of macrophages in shoulder plaque regions, thinning of
the ﬁbrous cap in these regions, MMP-2 and MMP-9,
have stimulated great interests in the potential roles of
MMPs in plaque rupture [117]. According to the follow-
up data, plasma MMP-9 during acute coronary syndromes
is increased two to three times compared with controls
[118]. However, whether MMP-9 becomes the independent
prognostic marker still requires further and large-scale
research.AtargetedapproachthatinhibitsMMPshasalready
been considered [119].
4.6. Proinﬂammatory Mediators Associated with Macrophage:
C-Reactive Protein (CRP). Multiple large-scale studies
demonstrate that CRP strongly and independently predicts
adverse cardiovascular events, including myocardial infarc-
tion, ischemic stroke, and sudden cardiac death because of
atherosclerosis [120, 121]. However, these mechanisms have
not been comprehensively identiﬁed. CRP is found close
to LDL and macrophages within atherosclerotic plaques.
Recently, several reports demonstrated that CRP could
modulate endothelial functions and leukocyte activities.
CRP also induces the production of IL-1α,I L - 1 β,I L - 6 ,
CXCL1, and CXCL8 by human monocytes in vitro.I n
contrast to these proinﬂammatory properties, CRP also
displays anti-inﬂammatory eﬀects through the upregulation
of liver X receptor-α [122]. CRP binds to minimally
modiﬁed (mm) LDL to prevent the foam cell formation
from macrophages [123]. Based on animal experiments
and the cardiovascular risk stratiﬁcation in primary
prevention populations, the Centers for Disease Control and
Prevention and the American Heart Association assigned
CRP as an independent marker of cardiovascular risk. The
recommended cut-oﬀ points in clinical practice are 1mg/L
for low-risk and 3mg/L for high-risk individuals [124].
4.7. Superoxide Production: Reactive Oxygen Species (ROS).
Extensive ROS has been implicated in atherosclerosis by
inducing the chronic activation of vascular endothelium
and components of immune systems. It has been demon-
strated that superoxide production from both macrophages
and vascular cells plays a critical role in atherogene-
sis [125]. When ROS production exceeds the scaveng-
ing capacity of cellular antioxidant systems, the resulting
oxidative stresses damage lipids, membranes, proteins, and
DNAs.
4.8. Emerging Future Biomarkers: MicroRNAs (miRNAs).
miRNAs are highly conserved single-stranded noncoding
small RNAs that control cellular functions by either degrad-
ing mRNAs or inhibiting their translation [126]. The
involvementofmiRNAsindiﬀerentaspectsofcardiovascular
diseases has emerged as an important research ﬁeld. The
dysregulation of many individual miRNAs has been linked to
the development and progression of cardiovascular diseases.
The forced expression or suppression of a single miRNA
is enough to cause or alleviate pathological changes. The
roles of miRNAs in the pathogenesis of heart and vascular
diseases suggest the possibility of using miRNAs as a
potential diagnostic biomarker and/or therapeutic target for
cardiovascular diseases [127].
Aspreviouslydiscussed,acriticalstepinthedevelopment
of chronic inﬂammatory atherosclerotic diseases is the
migration of circulating monocytes into the subendothelial
space and their diﬀerentiation into macrophages. A recent
study showed that miR-125a-5p mediates lipid uptake and
decreases the secretion of some inﬂammatory cytokines,
including IL-2, IL-6, TNF-α,a n dT G F - β from oxLDL-
stimulated monocyte-derived macrophages[128].Thetarget
gene of miR-125a-5p has been found to be ORP9, which has
diverse roles in the regulation of lipid metabolism, including
vesicle transport, andcellcycleregulationanddiﬀerentiation
[129]. miR-33 appears to regulate both HDL biogenesis
in the liver and cellular cholesterol eﬄux [130]. miR-33
is an intronic miRNA located within the gene encoding
sterol-regulatory element-binding factor-2, a transcriptional
regulator of cholesterol synthesis. miR-33 modulates the
expression of genes that are involved in cellular cholesterol
transport. It appears to be regulated by dietary cholesterol in
vivo and have several roles in cholesterol homeostasis [131].
miR-33 targets the 3  UTR of ABCA1 in mouse peritoneal
macrophages and human cells [131, 132], resulting in
reduced atherogenic cholesterol eﬄux to apolipoprotein
A1. Similarly, in a mouse model, the lentiviral delivery of
miR-33 represses ABCA1 expression in the liver, leading
to a reduction in circulating HDL levels, whereas mice
expressing anti-miR-33 demonstrate increased plasma HDL
levels [132]. Clearly, miR-33 is a promising target for the
treatment of abnormalities in lipoprotein metabolism that
frequently contributes to atherosclerosis.
5. Conclusion
The accumulation of macrophages laden with cholesterol in
the vascular intima is the hallmark of fatty plaque formation
in atherosclerosis. Understanding the mechanisms involving
macrophages is critical for the prognosis, diagnosis, and
treatment of atherosclerosis. However, because most papers
cited in this paper show data from cultured macrophages
and animal models, these data may not completely reﬂect
the process in human diseases. As noted by Rosenfeld et al.,
mouse atherosclerosis is not a good model for true plaque
rupture or thrombosis [133]. In contrast, some papers on
atherosclerosis emphasise the fact that many genes involved
in macrophages have “major and critical” functions for
plaques,whichcomplicatestheprocessofdetermininguseful
biomarkers for atherosclerosis. Human genetic studies and
mechanism-based clinical trials should be performed in the
future.
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